title: Persistence with cholinesterase inhibitor therapy in a population-based cohort of patients with Alzheimer's disease.
abstract: OBJECTIVE
  To estimate the risk (and determinants) of discontinuing cholinesterase inhibitors (ChEIs) in a population-based sample of Alzheimer's disease (AD) patients.
  
  
  METHODS
  This is a retrospective cohort study based on linked de-identified administrative health data from the province of Saskatchewan, Canada. The cohort included all AD patients receiving a ChEI prescription during the first year of provincial coverage (2000-2001). Persistence was defined as no gap of 60+ days between depletion and subsequent refill of a ChEI prescription. Kaplan-Meier analysis was used to estimate the risk of discontinuation over 40 months. Cox regression with time-varying covariates was used to assess risk factors for ChEI discontinuation.
  
  
  RESULTS
  The sample included 1080 patients (64% female, average age 80 +/- 7 years). Baseline mean (SD) Mini-Mental State Examination (MMSE) and Functional Activities Questionnaire (FAQ) scores were 20.8 (4.4) and 17.5 (7.7), respectively. Over 40 months, 84% discontinued therapy. The 1-year risk of discontinuation was 66.4% (95%CI 63.5-69.3%). Discontinuation was significantly more likely for females (adjusted HR 1.34, 95%CI 1.16-1.55) and among those with lower MMSE scores (2.52, 2.01-3.17 if <15), not receiving social assistance (1.25, 1.07-1.45), and paying at least 65% of total prescription costs (1.51, 1.30-1.74). It was significantly less likely for patients with frequent physician visits (0.78, 0.66-0.93, for 7-19 vs. <7 visits), higher Chronic Disease Scores (0.74, 0.61-0.89, for 7+ vs. <4), and FAQ scores of 9+ (0.82, 0.69-0.99).
  
  
  CONCLUSIONS
  The likelihood of discontinuing ChEI therapy was high in this real-world sample of AD patients. Significant predictors included clinical, socioeconomic, and practice factors.
authors.affiliation: Methodology Unit, Canadian Institute for Health Information, Ottawa, Ontario, Canada.
authors.forename: Joseph E
authors.initials: JE
authors.lastname: Amuah
authors.forename: David B
authors.initials: DB
authors.lastname: Hogan
authors.forename: Misha
authors.initials: M
authors.lastname: Eliasziw
authors.forename: Alison
authors.initials: A
authors.lastname: Supina
authors.forename: Patricia
authors.initials: P
authors.lastname: Beck
authors.forename: Winanne
authors.initials: W
authors.lastname: Downey
authors.forename: Colleen J
authors.initials: CJ
authors.lastname: Maxwell
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D009483:Neuropsychological Tests; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D012525:Saskatchewan; D012737:Sex Factors; D012959:Socioeconomic Factors; D013997:Time Factors
chemical_list: D002800:Cholinesterase Inhibitors